Olopatadine in the management of allergic conjunctivitis

被引：0
|
作者：
Schmidt, S.
机构：
来源：
SA PHARMACEUTICAL JOURNAL | 2020年 / 87卷 / 01期
关键词：
0.1-PERCENT; HYDROCHLORIDE; EFFICACY;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：41 / 44
页数：3
相关论文
共 50 条
  • [41] Olopatadine reduces ocular signs and symptoms associated with allergic conjunctivitis 16 hours after instillation
    Abelson, MB
    Gomes, PJ
    Welch, DL
    Pasquine, TA
    Turner, FD
    Bergamini, MVW
    Robertson, SM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U311 - U311
  • [42] Perception and quality of life associated with the use of olopatadine 0.2% (Pataday™) in patients with active allergic conjunctivitis
    Scoper, Stephen V.
    Berdy, Gregg J.
    Lichtenstein, Steven J.
    Rubin, Jay M.
    Bloomenstein, Marc
    Prouty, Robert E.
    Vogelson, Cullen T.
    Edwards, Michael R.
    Waycaster, Curtis
    Pasquine, Terri
    Gross, Robert D.
    Robertson, Stella M.
    ADVANCES IN THERAPY, 2007, 24 (06) : 1221 - 1232
  • [43] Olopatadine 0.2% is effective for the once daily treatment of the ocular signs and symptoms associated with allergic conjunctivitis
    Abelson, MB
    Gomes, PJ
    Welch, DL
    Pasquine, TA
    Vogelson, C
    Gross, RD
    Turner, FD
    Bergamini, MVW
    Robertson, SM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U527 - U527
  • [44] ICON Diagnosis and management of allergic conjunctivitis
    Bielory, Leonard
    Delgado, Luis
    Katelaris, Constance H.
    Leonardi, Andrea
    Rosario, Nelson
    Vichyanoud, Pakit
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 124 (02) : 118 - 134
  • [45] Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis
    Yaylali, V
    Demirlenk, I
    Tatlipinar, S
    Özbay, D
    Esme, A
    Yildirim, C
    Özden, S
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2003, 81 (04): : 378 - 382
  • [46] Perception and quality of life associated with the use of olopatadine 0.2% (Pataday™) in patients with active allergic conjunctivitis
    Stephen V. Scoper
    Gregg J. Berdy
    Steven J. Lichtenstein
    Jay M. Rubin
    Marc Bloomenstein
    Robert E. Prouty
    Cullen T. Vogelson
    Michael R. Edwards
    Curtis Waycaster
    Terri Pasquine
    Robert D. Gross
    Stella M. Robertson
    Advances in Therapy, 2007, 24 : 1221 - 1232
  • [47] Olopatadine 0.2% reduces the primary sign and symptom of allergic conjunctivitis during peak pollen periods
    Greiner, JV
    Abelson, MB
    Gomes, PJ
    Vogelson, CT
    Pasquine, TA
    Gross, RD
    Turner, FD
    Bergamini, MVW
    Robertson, SM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U532 - U532
  • [48] A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis
    Rosenwasser, Lanny J.
    Mahr, Todd
    Abelson, Mark B.
    Gomes, Paul J.
    Kennedy, Kathryn
    ALLERGY AND ASTHMA PROCEEDINGS, 2008, 29 (06) : 644 - 653
  • [49] Treatment with olopatadine and naphazoline hydrochloride reduces allergic conjunctivitis in mice through alterations in inflammation, NGF and VEGF
    Quan, Lin
    He, Hua
    MOLECULAR MEDICINE REPORTS, 2016, 13 (04) : 3319 - 3325
  • [50] Local allergic conjunctivitis: a phenotype of allergic conjunctivitis
    Yamana, Yasuo
    Fukuda, Ken
    Ko, Ryota
    Uchio, Eiichi
    INTERNATIONAL OPHTHALMOLOGY, 2019, 39 (11) : 2539 - 2544
12345